Gilead Sciences (NASDAQ: GILD) has entered into a definitive agreement to acquire Germany-based Tubulis GmbH, a private clinical-stage biotechnology company, for USD 3.15 billion in upfront cash plus up to USD 1.85 billion in contingent milestone payments. The transaction consolidates Tubulis' Tubutecan linker-payload technology and its clinical-stage ADC pipeline into Gilead's oncology division, building on a prior collaboration announced in December 2024.
Under the sale and purchase agreement, Gilead acquires all outstanding equity of Tubulis on a cash-free, debt-free basis, with the upfront consideration payable at closing subject to customary adjustments. The USD 1.85 billion in contingent payments is structured as milestone-based, though individual triggering events and sub-categories are not disclosed. Gilead intends to finance the transaction through a combination of cash on hand and senior unsecured notes. The transaction is expected to close in the second quarter of 2026, subject to expiration or termination of applicable regulatory filings and other customary conditions. The deal conveys worldwide rights across all Tubulis platforms and pipeline assets, with no geographic carve-outs disclosed.
NaPi2b-directed TOPO1i ADC and the tubutecan platform
The primary clinical asset entering Gilead's pipeline is TUB-040, a NaPi2b-directed topoisomerase-I inhibitor (TOPO1i) ADC currently in Phase Ib/II development for platinum-resistant ovarian cancer and non-small cell lung cancer (NSCLC). NaPi2b, a sodium-phosphate cotransporter, is overexpressed across multiple solid tumor types, providing a target rationale for payload delivery in gynecologic and thoracic malignancies. TUB-040 incorporates Tubulis' proprietary Tubutecan linker-payload technology, which the company positions as conferring durable on-tumor delivery and sustained anti-tumor activity based on preclinical models and early clinical proof-of-concept data in platinum-resistant ovarian cancer. A second clinical candidate, TUB-030, targets the oncofetal antigen 5T4 and has generated initial clinical data across multiple solid tumor types, though detailed efficacy and safety readouts are not disclosed in the source material.
The Tubutecan platform addresses a recognized limitation in ADC design: the balance between systemic payload stability and intratumoral release efficiency. Conventional ADC linker-payload combinations face trade-offs between premature extracellular payload release — which drives off-target toxicity — and insufficient intratumoral drug liberation. Tubulis' site-specific conjugation approach, which also encompasses the Tub-tag enzymatic conjugation technology, is designed to generate homogeneous drug-antibody ratio (DAR) products with defined conjugation sites, reducing the heterogeneity that contributes to nonspecific biodistribution and narrowed therapeutic windows in earlier-generation ADCs.